Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 Genes Involved in the Double-Strand Break Repair Pathway Predict Glioblastoma Survival
Yanhong Liu, Sanjay S. Shete, Carol Jean Etzel et al. · Journal of Clinical Oncology · 2010
PURPOSE: Glioblastoma (GBM) is the most common and aggressive type of glioma and has the poorest survival. However, a small percentage of patients with GBM survive well beyond the established median. Therefore, identifying the genetic variants that influence this small number of unusually long-term survivors may provide important insight into tumor biology and treatment. PATIENTS AND METHODS: Among 590 patients with primary GBM, we evaluated associations of survival with the 100 top-ranking glioma susceptibility single nucleotide polymorphisms from our previous genome-wide association study using Cox regression models. We also compared differences in genetic variation between short-term survivors (STS; or= 36 months), and explored classification and regression tree analysis for survival data. We tested results using two independent series totaling 543 GBMs. RESULTS: We identified LIG4 rs7325927 and BTBD2 rs11670188 as predictors of STS in GBM and CCDC26 rs10464870 and rs891835, HMGA2 rs1563834, and RTEL1 rs2297440 as predictors of LTS. Further survival tree analysis revealed that patients >or= 50 years old with LIG4 rs7325927 (V) had the worst survival (median survival time, 1.2 years) and exhibited the highest risk of death (hazard ratio, 17.53; 95% CI, 4.27 to 71.97) compared with younger patients with combined RTEL1 rs2297440 (V) and HMGA2 rs1563834 (V) genotypes (median survival time, 7.8 years). CONCLUSION: Polymorphisms in the LIG4, BTBD2, HMGA2, and RTEL1 genes, which are involved in the double-strand break repair pathway, are associated with GBM survival.
Cited by 110 works. doi:10.1200/jco.2009.26.6213 Open-access PDF
Authors
- Yanhong Liu
- Sanjay S. Shete
- Carol Jean Etzel
- Michael E. Scheurer
- George Α. Alexiou
- Georgina Armstrong
- Spyros Tsavachidis
- Fu‐Wen Liang
- Mark R. Gilbert
- Ken D. Aldape
- Terri S. Armstrong
- Richard S. Houlston
- Fay J. Hosking
- Lindsay B. Robertson
- Yuanyuan Xiao
- John K. Wiencke
- Margaret Wrensch
- Ulrika Andersson
- Beatrice S. Melin
- Melissa L. Bondy
References
- Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma Trials
- A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival
- Assessing the Probability That a Positive Report is False: An Approach for Molecular Epidemiology Studies
- What's going on 放射線 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. N Engl J Med. 2005; 352: 987-96. PMID: 15758009.--神経膠腫に対する治療として、放射線治療とテモゾロマイドの併用が世界的な標準的治療となりうることを示唆する論文
- DNA Topoisomerases: Structure, Function, and Mechanism
- Cellular roles of DNA topoisomerases: a molecular perspective
- An Introduction to Recursive Partitioning Using the RPART Routines